Drugs targeting mGluRs achieve their therapeutic effects by reducing excitatory drive, either via antagonism of Group I mGluRs or activation of Group II and III mGluRs (one exception is represented by the use of mGluR5 PAMs for the management of cognitive deficits linked with schizophrenia). This evidence concerns the gene GRM5 and schizophrenia.